N/A N=342 Psychophysiologic Predictors of Post-deployment Mental Health Outcomes
Post-traumatic Stress Disorder
Primary: The PTSD Checklist - Military Version — 22.2; 23.7; 23.8; 25.9 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)
Healthy Volunteers
Primary: Change From Baseline in Peak-to-Peak Amplitude of Motor-evoked Potential (MEP) Obtained With Single-pulse Transcranial Magnetic Stimulation (TMS) for TAK-653 at 2.5…
Phase 2 N=15 ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck · HPV Positive Oropharyngeal Squamous Cell Carcinoma
Primary: HPV-Specific T Cell Response Rate — 0.333 proportion of participants
N/A N=19 Intensive Home-based Treadmill Training and Walking Attainment in Young Children With Cerebral Palsy
Cerebral Palsy
Primary: Gross Motor Function Measure Dimension E — 15.6; 12.7; 18.7; 17.1 score on a scale
N/A N=418 Observational Study of OCT in a Patients Undergoing FFR
Coronary Artery Disease
Primary: Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting — 0; 6.7; 6.2; 0.2 Percentage of per-subject incidence
N/A N=9 Long QT Syndrome and Sleep Apnea
Long QT Syndrome · Sleep Apnea
Primary: QT Interval (Corrected) Baseline Visit — 453.4 square root of seconds — p=0.73
Phase 2 N=11 Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
Alopecia Universalis (AU) · Alopecia Totalis (AT)
Primary: Double Blind Period: ATI-50002 Levels in Scalp Biopsy (ng/g) - Pharmacodynamic (PD) Population at Day 2 and Day 29 — 166.0; 579.7; NA; 5710.0 ng/g
Phase 4 N=96 Effect of Vitamin D Supplementation on Bone Turnover Markers During PrEP in MSM
Patient Adherence
Primary: Change in Total Procollagen Type 1 N-terminal Propeptide (a Marker of Bone Formation) [P1NP] Levels — -27.6; -2.5 pg/mL
Phase 2 N=12 Valchlor in the Treatment of Lichen Planopilaris
Lichen Planopilaris
Primary: Change in Lichen Planopilaris Activity Index (LLPAI) — -42.9; -66.7 percentage of change from baseline — p=0.014
N/A N=475 Effectiveness of Two Silicone Dressings for Sacral and Heel Pressure Ulcer Prevention
Pressure Ulcer
Primary: Number of Pressure Ulcers Category II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum (Proportion) — 6; 22 Pressure ulcer
Phase 1 N=61 A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)
Type 2 Diabetes Mellitus
Primary: Number of Participants Who Experienced at Least One Adverse Event (AE) (Part 1) — 3; 4; 2; 0 Participants
N/A N=335 Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
Infectious Disease · Pneumonia, Bacterial · Influenza
Primary: Mean Change in Knowledge and Awareness About Vaccine-Preventable Diseases — 3.5; 4.9; 1.3; 1.8 Scores on a scale — p=0.0081
Phase 1 N=32 Memory Modulation by Pain During Anesthesia
Amnesia · Pain · Anesthesia
Primary: Memory Testing — 1.20; .56; .82; 1.18 d' score
Phase 2 N=160 Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer
Non-small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 2.96; 3.02 months — p=0.544
Phase 2 N=35 Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Rate of Complete Response/Complete Remission (CR), as Assessed by Investigator Using Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008…